Actualizado 03/06/2009 18:40
- Comunicado -

Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Ca

Media Contacts: BiPar Sciences, Terri Clevenger, Tel : +1-203-856-4326, Email : tclevenger@continuumhealthcom.com; Stephan Herrera, Tel : +1-415-794-4005, Email : sherrera@biparsciences.com; sanofi-aventis, Salah Mahyaoui, Tel : +33-1-53-77-40-31, Mobile : +33-6-73-68-78-88, Email : salah.mahyaoui@sanofi-aventis.com

Contenido patrocinado